MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) will likely be posting its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect MaxCyte to post earnings of ($0.14) per share and revenue of $7.98 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

MaxCyte Price Performance

MaxCyte stock opened at $3.51 on Friday. The firm has a 50 day simple moving average of $4.26 and a 200-day simple moving average of $4.00. The stock has a market capitalization of $371.92 million, a PE ratio of -10.32 and a beta of 1.35. MaxCyte has a 12-month low of $3.16 and a 12-month high of $5.26.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.